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Pioglitazone is one of the thiazolidinedione anti-diabetic drugs which have been used
for the treatment of non-insulin dependent diabetes mellitus. This study aims at
investigating the biochemical effects and safety of pioglitazone (PIO) at various
concentrations in female Wistar rats. A total  of  28 rats  were  randomly  divided  into
four groups of seven animals each. Groups 1-4 were given 0.5 mL kgG1 b.wt., dayG1  of
distilled water as normal control; 15, 30 and 45 mg kgG1 b.wt., dayG1 of PIO,
respectively as treatment groups 2, 3 and 4, respectively for 28 days. Using standard
biochemical kits and reported chemical procedures, plasma biochemical parameter and
organ lipid peroxidation effects were determined in all the groups. There was significant
increase (p<0.05) in plasma total protein concentration of group 3 and 4 in comparison
with control. There was also significant (p<0.05) reduction in total and LDL cholesterols
in PIO-treated groups and concentration of TBARS was reduced in the liver and heart
of PIO-treated groups in comparison with normal control. There was no significant
alteration in the concentrations and activities of liver and kidney function markers of
PIO treated groups in comparison with normal control groups. Pioglitazone at highest
concentration of 45 mg kgG1 b.wt., for the duration of 28 days did not elicit any
measurable biochemical toxicity on non-diabetic rat model.
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INTRODUCTION
Diabetes has been reported as one of the five leading
causes of death in the world1. It is characterized by persistent
hyperglycaemia, which is associated with abnormalities in
carbohydrate, protein and lipid metabolism caused by failure
of insulin secretion and/or increased cellular resistance to
insulin. Type 2 diabetes mellitus is a disorder characterized by
insulin  resistance  and  a  progressive  decline  in  pancreatic
β-cell function associated with increasing hyperglycaemia2. A
chronic hyperglycaemia of diabetes is associated with severe
microvascular and macrovascular problems, which includes
neuropathy, nephropathy, retinopathy, cardiovascular and
peripheral vascular diseases3,4. Diabetes is the most prevalent
metabolic syndrome worldwide with an incidence of 2.8%
across all age groups in 2000 and projected to increase to 4.4%
by 20305. The prevalence of diabetes in Nigeria is about 2.2%
of her population, with urban communities having a higher
overall prevalence than that of the rural communities6,7. The
number of people with diabetes is increasing due to population
growth, aging, urbanization and increasing prevalence of
obesity and physical in-activities.
Thiozolidinediones (TZD), the insulin sensitizers used for
the management of diabetes were introduced in 1997. They
have been classified as novel group of insulin-sensitizing
mediators,  capable  of  improving  insulin  action  with  a
post-insulin  receptor  mechanism  of  action  by  acting  as  a
synthetic  agonist  of  peroxisome  proliferator-activated
receptors γ (PPARs-γ) predominantly expressed in the
adipocytes and to a lesser extent in the muscle and liver
tissues2. They alter gene transcription influencing significant
changes in carbohydrate and lipid metabolism, resulting in
changed amounts of protein synthesis and hence effecting
metabolic alterations2. Troglitazone, the first agent of TZD to
be approved, was effective in controlling glycaemia but was
withdrawn from the market in 2000 following reports of fatal
hepatotoxicity. The prospect of rosiglitazone is undecided
owing to a possible risk of myocardial infarction and
cardiovascular-related deaths2,8. 
Pioglitazone (PIO) is a prescription drug, the second of
the thiazolidinediones (TZD) class with hypoglycemic activity
for the management of diabetes. It can be used as monotherapy
or in combination with metformin or sulphonylureas for the
management of diabetes  in  obese  and  non-obese patients
who have failed  other  conservative measures9. There is
limited information on the sub-chronic toxicity studies of
pioglitazone in non-diabetic experimental animal model.
Reported clinical cases of pioglitazone-induced side-effects
with less severe consequences have been reported10,11. In the
few reported cases, most patients improved symptomatically
2-4 weeks following discontinuation of the drug, with
normalization of relevant biomarkers12. Acute toxicity of
pioglitazone has been associated with ventricular hypertrophy
with congestion of the liver and kidney in mice10. As a result
of the reported associated toxicity observed with
thiozolidinediones, the use of pioglitazone in the management
of type 2 diabetes and the paucity of report on sub-chronic
toxicity of pioglitazone. The present study was undertaken to
assess the toxicological effects of pioglitazone in a 28 day
study design.
MATERIALS AND METHODS
Materials: Pioglitazone hydrochloride, C19H20N2O3S.HCl,
with molecular weight of 392.90 (CAS 112529-15-4) was
purchased from Tokyo Chemicals Industry Japan, while all
other chemicals were from Sigma-Aldrich (USA) or Randox
Laboratories Ltd., UK and were of analytical grade.
Animals: Albino  Wistar  rats  (n = 28,  females) weighing
(150-200 g) were used for the study. Animals were procured
from the Central Animal House of the Department of
Biochemistry, Federal University of Agriculture, Abeokuta,
Ogun State.
Sub-acute toxicity: All  the  animals  were  acclimatized  for
14 days under standard husbandry conditions. The animals
were housed in standard laboratory cages and maintained
under standard laboratory conditions. Rats had free access to
food  and  water ad  libitum  throughout the experimental
period, which was replenished daily. Animal handling and
experimental procedures were according to international
procedures. Ethical approval was obtained from Covenant
University Ethics Committee, Ogun state and Nigeria Institute
of Medical Research (NIMR) Ethics Committee, Lagos state
with project approval number IRB/13/227. Rats were
randomized into four groups of seven animals each. They were
weighed before the commencement of treatment and weekly
throughout the duration of the study. Group 1 represent
Normal Control (NC) and received 0.5 mL of distilled water
while groups 2-4 received pioglitazone in three different doses
of 15, 30 and 45 mg kgG1 b.wt., respectively. The animals
were dosed daily by gastric intubation. The physical
appearance and daily activities of the rats, such as eating
patterns and signs of abnormalities were observed and
recorded. On the 29th day after treatment, experimental
animals were put under light ether anaesthesia and latter
sacrificed13. Blood samples were collected by cardiac puncture
into heparin tubes. The lungs, hearts, intestines, kidneys and
livers of rats were also excise, washed in normal saline,
weighed and stored at -20EC. Liver and kidney markers of
organ toxicity were evaluated in the experimental animals
while lipid peroxidation assessment was carried out in all
excised organs.
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Biochemical analyses: The blood samples in heparin tubes
were centrifuged at 3000 rpm for 10 min to collect the blood
plasma. The blood plasma was analysed for parameters such
as  total  protein,  albumin,  urea,  creatinine,  triglyceride,
aspartate    aminotransferase,    alanine    aminotransferase,
alkaline phosphatase, cholesterol, High Density Lipoprotein-
Cholesterol (HDL-C), Low Density Lipoprotein-Cholesterol
(LDL-C), total bilirubin and direct bilirubin using Randox test
kit (Randox Laboratories Ltd., UK).
Determination of thiobarbituric reactive substances
concentration: Blood concentration of thiobarbituric acid
reactive substances (TBARS) is an index of lipid peroxidation
and oxidative stress. Concentration of thiobarbituric acid
reactive substances (TBARS) was determined by the methods
of Buege and Aust14 as described by Ogunlana et al.15. Aliquot
of tissue homogenate (0.1 mL) in 0.04 M tri-HCl (pH 8.3)
buffer was treated with 2.0 mL of TBA-TCA-HCL, 1:1:1
reagent (thiobarbituric acid (TBA) 0.37%, 0.25 N HCl and
15% (w/v) TCA) and incubated at 95EC for 15 min. The
TBARS content was determined using the extinction
coefficient of 155 nMG1 cmG1 at 535 nm. 
Statistical analysis: All results are reported as means and
standard errors of means (Mean±SEM). Statistical evaluations
of the data were initially tested for normality and for
homogeneity of variances. Comparisons between groups were
performed using one way analysis of variance (ANOVA)
followed by Dunnett’s control comparison tests using R
statistical programming language (version 3.1.1). All
comparisons were made relative to untreated controls and a
difference with a p<0.05 was considered significant. Data were
visualized by graph pad prism version 6.
RESULTS
Table 1  shows  the  biochemical  effect  of  pioglitazone
on  liver  function  markers  of  rats.  There  was  a   significant
increase (p<0.05) in serum Total Proteins (TP) in the 30 and
45 mg kgG1 of pioglitazone treatment groups. However, no
significant change (p>0.05) was observed in other liver
function biochemical markers assayed in this study in all
treatment groups when compared with the control. Table 2
shows the biochemical effect of pioglitazone on kidney
function markers of rats. There was no observed significant
change (p>0.05) in the kidney function biochemical
parameters assayed in this study in all treatment groups when
compared with the control. Figure 1 shows the effects of
pioglitazone  on  lipid  profile of experimental rats. There was
a significant decrease (p<0.05)  in  total  plasma  cholesterols
and low density lipoprotein-cholesterols was observed in
pioglitazone treatment groups when compared with the
control. There was no significant (p>0.05) change in the
plasma  levels   of   triglycerides   and   high  density
lipoprotein-cholesterols  when  compared  with  the  control.
Figure 2  shows  the  effects  of pioglitazone on concentration
of thiobarbituric acid reactive substances (TBARS) in major
organs of experimental rats. There was a significant decrease
(p<0.05)  in  the  concentrations  of  TBARS  in  the  liver  and
heart of rats in pioglitazone treated groups when compared
with the control. However, no significant (p>0.05) changes
were observed in the TBARS concentration of the kidneys,
intestine and lungs in pioglitazone treated groups when
compared to the control.
DISCUSSION
This study demonstrates that pioglitazone, an antidiabetic
drug at moderately high doses of 45 mg kgG1 b.wt., of rats did
not exhibit a significant biochemical toxicity in the major
tested organs of healthy non-diabetic rats with drug exposure
for a period of 28 days. Pioglitazone, a selective agonist of
nuclear peroxisome proliferator activated receptor γ (PPAR-γ)
regulates the transcription of genes encoding proteins involved
in carbohydrate and lipid metabolisms. It increases glucose
uptake  in  muscles  and  adipose  tissue  and decreases hepatic
Table 1: Biochemical effect of pioglitazone on liver function markers of rats after 28 days of oral administration
Groups AST (U LG1) ALT (U LG1) ALP (U LG1) Alb (mg dLG1) DB (mg dLG1) TB (mg dLG1) TP (g dLG1)
Control 3.387±1.59 6.040±3.34 13.200±2.93 3.192±0.10 0.286±0.08 0.382±0.09 8.363±036
15 mg kgG1 5.727±3.27 4.962±5.37 10.010±1.39 3.490±0.17 0.617±0.25 0.687±0.16 10.300±0.75
30 mg kgG1 5.428±2.06 2.427±1.50 10.950±1.71 3.626±0.12 0.370±0.09 0.470±0.09 11.570±0.51*
45 mg kgG1 5.953±1.98 3.213±3.09 8.635±3.64 3.797±0.19 0.315±0.09 0.657±0.10 13.640±0.55*
AST: Aspartate  aminotransferase, ALT: Alanine  aminotransferase, ALP: Alkaline phosphatases,  Alb:  Albumin,  DB:  Direct  bilirubin, TB: Total  bilirubin,
TP: Total protein. Results expressed as Mean±SEM of  7 replicates study. *Values are significantly different at p<0.05 compared with control group
Table 2: Biochemical effect of pioglitazone on kidney function markers of rats after 28 days of oral administration
Groups Urea (mg dLG1) Creatinine (mg dLG1) Na+ (mmol LG1) K+ (mmol LG1) ClG (mmol LG1) HCO3G (mmol  LG1)
Control 60.84±3.55 0.820±0.07 144.5±1.71 9.250±1.31 117.5±2.10 21.50±5.14
15 mg kgG1 56.80±3.18 0.820±0.05 145.8±3.82 10.500±1.04 119.2±1.18 22.00±5.45
30 mg kgG1 47.48±5.19 0.858±0.03 143.7±2.88 10.830±1.08 119.5±6.14 20.33±5.64
45 mg kgG1 48.05±1.97 0.910±0.10 147.0±2.54 9.667±0.61 124.3±2.56 17.50±3.77
Na+: Sodium ions, K+: Potassium ions, ClG: Chlorine ions, HCO3G: Bicarbonate ions. Results expressed as Mean±SEM of  7 replicates study
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Fig. 1(a-d):Effects  of pioglitazone  on  lipid  profile  of  Wistar  albino  rats  after  28  days  of  oral  administration. Results
expressed as  Mean±SEM  of  7  replicates  study,  concentrations  of  plasma  (a) Total cholesterol,  (b)  Triglycerides,
(c) HDL-cholesterol and (d) LDL-cholesterol. *Values are significantly different at p<0.05 compared with control
group
gluconeogenesis as well as blood glucose level. Pioglitazone
enhances insulin action on liver, adipose tissue and skeletal
muscles and thus improving glycaemic control in persons with
type 2 diabetes10. All biochemical tests carried out on the
blood and tissue homogenate of experimental rats are indices
for the assessment of health status for human. In the current
study kidney markers were used to assess the functionality and
cellular integrity of the kidney. Plasma concentrations of urea,
creatinine, sodium (Na+), potassium (K+), chloride (ClG) and
bicarbonate (HCO3G) were not significantly affected by
pioglitazone  administration.  However,  in  streptozotocin
(STZ) induced diabetic rats, after undergoing renal
ischemia/reperfusion  (I/R)  injury   and   PIO   treatment   for
15 days, the animals exhibited significantly higher serum
creatinine, urea and uric acid levels as compared to I/R control
group alone while treatment with glimepiride significantly
reduced serum uric acid when compared to control group16.
The  renoprotective   activity   of   pioglitazone   against
cisplatin-induced acute renal failure in experimental animals
has previously been reported17-19, these corroborate the
findings in this study. The concentration of liver function
markers are indices for the assessment of hepatocellular
functionality and integrity. The insignificant changes of liver
function markers in this experimental rat model after high
doses of PIO, might be a function of the hepatoprotective
activity  of  pioglitazone.  Hepatoprotective  activity  of PIO
has been reported in high fat diet-fed rats for 16 weeks20,21.
Observed increase in total plasma protein at moderately high
concentration  of  pioglitazone  in healthy  rats  does  not
correlate with increase in plasma albumin concentration. It is
proposed that pioglitazone did not significantly distraught the
osmotic albumin concentration in healthy experimental rat
model. The hepatoprotective  activity  of  pioglitazone  in  rat
model  of  diet-induced  alcoholic  fatty liver disease  and
acetaminophen-induced hepatotoxicity has been reported22,23.
However, acute high doses of pioglitazone have been
associated with ventricular hypertrophy with congestion in
liver and kidneys which can also happen with accidental
overdose of pioglitazone in patients10.
It has been established that type 2 diabetes has an
increased risk of all the manifestations of atherosclerotic
vascular disease and it is highly associated with cardiovascular
disease, a major contributing factor to this risk is the abnormal
lipid profile, dyslipidaemia, which is characterized by low
HDL-C, raised triglyceride and predominance of small dense
LDL-C particles24. Antidiabetes with the ability of attenuating
dyslipidaemia  is  a  better  monotherapy  or  in combination
with   other   antidiabetic   drugs.   Significant    reduction    in
13
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Fig. 2(a-e): Effects of pioglitazone on concentration of thiobarbituric acid reactive substances (TBARS) in major organs of
experimental rats after  28  days  of  oral  administration.  Concentrations  of  TBARS  in  the  (a)  Liver, (b) Kidney,
(c) Heart, (d) Intestine and (e) Lungs. Results expressed as Mean±SEM  of 7 replicates study. *Values are
significantly different at p<0.05 compared with control group
concentrations  of  LDL-cholesterol  and  total  plasma
cholesterol observed in this experiment  further  potentiate  the
ameliorative effect of  pioglitazone on lipid metabolism. The
lipid ameliorative effect of  PIO  in  this  study  was supported
by  the  reports  of  Rosenblatt  et al.25 and  Goldberg et al.26.
Etiopathogenesis of several chronic diseases has been
attributed to increase in generation of free radicals, which is a
product of normal cellular metabolism. Lipid is one of the
biological targets of oxidative stress. Lipid oxidation gives rise
to a number of secondary products which are mainly aldehydes
with ability to aggravate oxidative damage and toxicological
response. Malondialdehyde (MDA) is the principal and most
studied product of polyunsaturated fatty acid peroxidation27.
Concentration of MDA is directly correlated with levels of
thiobarbituric acid reactive substances (TBARS). Significant
reduction in the concentrations of TBARS observed in liver
and heart of experimental rats after pioglitazone exposure
further  potentiates  the   protective   effects   of  pioglitazone
at  these  concentrations   in  rat  model.  This  is  the  first 
time a comparative  assessment  on  TBARS  concentration in
different  organs  of  experimental  animal  model  is  been
carried   out.   Decrease    in    TBARS    concentrations    after
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pioglitazone treatment has been reported in humans28,29.
Pioglitazone-treated  non-alcoholic  steatohepatitis  (NASH)
rats has been reported to show significant reduction in
malondialdehyde levels when  compared  with  that  of  NASH
induced control group30. These previous studies further
substantiate the ameliorative effects of  PIO in both human and
animal models.
CONCLUSION
The study concludes that pioglitazone has no biochemical
toxicological effect in a sub-chronic 28 days study at
concentrations tested in non-diabetic animal model. However,
it is suggested that more researches on the effects of PIO
should be undertaken in diabetes using different experimental
models.
SIGNIFICANCE STATEMENTS
Pioglitazone (PIO) is a prescription drug which acts as
insulin sensitizer. It is used for the treatment of type 2 diabetes
and other related medical conditions such as hepatic steatosis.
The safety of pioglitazone is controversial despite its high
usage. There have been limited reports of its associated weight
gain, increase risk of congestive heart failure, liver disorder
and bladder cancer in patients undergoing treatment with
pioglitazone. Despite its continued usage, it is therefore
imperative to further study the toxicological effects of
pioglitazone and establish its biochemical and antioxidant
effects.
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